Dizal announces positive pooled data of sunvozertinib in EGFR TKI-resistant NSCLC: Shanghai, China Friday, December 13, 2024, 18:00 Hrs [IST] Dizal, a biopharmaceutical company co ...

In the conclusion to our interview with Joshua K. Sabari, MD, which focused on the first-line approval of amivantamab (Ami; ...

Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and ...

The FDA has granted Breakthrough Therapy Designation to datopotamab deruxtecan (Dato-DXd) for advanced EGFR-mutated non-small cell lung cancer.

Among Taiwan’s non-small cell lung cancer cases, approximately 55 percent involve an EGFR mutation, with deletion of exon 19 and exon 21 the most common mutations, treatable with first to ...

【导读】这项研究评估了鞘内培美曲塞（IP）对既往接受过治疗的表皮生长因子受体（EGFR）突变晚期非小细胞肺癌（NSCLC）患者脑膜转移瘤（LM）的治疗效果。2024年12月7日，中南大学湘雅医学院附属肿瘤医院张永昌教授团队在期刊《Heliyon》上发 ...

AstraZeneca and Daiichi Sankyo have shared the data they believe can secure approval for datopotamab deruxtecan (Dato-DXd) at ...

The FDA has granted Breakthrough Therapy designation to sacituzumab tirumotecan (sac-TMT) for advanced NSCLC with EGFR ...

The FDA granted breakthrough therapy status to sacituzumab tirumotecan in EGFR-mutated advanced non–small cell lung cancer.

The FDA has granted Breakthrough Therapy designation to sacituzumab tirumotecan for patients with advanced or metastatic ...

Merck ( MRK, Financials) stated that sacituzumab tirumotecan (sac-TMT) was designated a Breakthrough Therapy by the FDA for advanced or metastatic nonsquamous non-small cell lung cancer with epidermal ...

Merck (NYSE:MRK) said the FDA has granted Breakthrough Therapy designation for its antibody drug conjugate sacituzumab ...